FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Delaet Ingrid (Last) (First) (Middle) 12780 EL CAMINO REAL (Street)						Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX] 3. Date of Earliest Transaction (Month/Day/Year) 08/06/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) Chief Regulatory Officer 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person				
SAN DII	SAN DIEGO CA 92130 (City) (State) (Zip)				Di	Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication												ting
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															d to			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					action	tion 2A. Deemed Execution Date,			3. 4. Sec Transaction Dispos Code (Instr. 5)		4. Securi	rities Acquired (A) or ed Of (D) (Instr. 3, 4 and		5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock 0					5/2024				Code	v	Amount 273	(A) or (D)	Price	Transac (Instr. 3	tion(s)	D		
Common Stock 08/06/2											273	D	\$147		6,607			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Code (Ins				6. Date E Expiratio (Month/E	n Date)	Amount of Securities Underlying Derivative Seci (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly Ow For Oir Or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock	\$79.02	08/06/2024			M			273	(2)		01/31/2032	Common Stock	273	\$0	4,081		D	

Explanation of Responses:

- 1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.
- 2. The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Remarks:

/s/ Darin Lippoldt, Attorney-in-08/08/2024

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.